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Introduction  
Based on the figures of Ukrainian statistics, like in majority of countries all 
over the world, cardio-vascular diseases take the first place in sickness and mortality 
rate in population. Among them, there are arteriosclerosis and its complications 
(myocardial infarction, aortic aneurysm, insult, thromboembolism etc.) [1]. WHO 
research shows that traditional approaches in the treatment of these and other 
common multifactorial diseases are ineffective and lead to substantial economic costs 
[2]. The problem is low efficiency of therapeutic and preventive measures related to 
the absence of etiological orientation due to insufficient understanding of the 
fundamental mechanisms that form the overwhelming majority of multifactorial 
diseases. Recently, research efforts of our foreign scientists have focused on the 
causes and mechanisms of these diseases. It was proved that compound coordinated 
action of genetic factors and environment are fundamental for forming these    
diseases [3]. 
With the development of molecular genetic technologies there have been  
ample opportunities for studying the genetic components of diseases. Today, a 
significant amount of accumulated data on the participation of various polymorphic 
genes has predispositioned  the formation of multifactorial pathology [4]. 
However, inspite of the success of the global scientific community in 
understanding the human genome to have a relatively small number of genes, all of 
which are only partially explained in some of the links in the pathogenesis of 
myocardial infarction. Relative to the Ukrainian population such data are 
inconsiderable and disputable.  
Considering that MGP probably brings effects on artery calcification 
development which is considered to be one of the main signs of degeneration process, 
it can be assumed that the genetic polymorphism of the promoter region may effect 
on the level of gene expression, MGP, and the variability of the 4th exon - the 
qualitative characteristics of the protein. Published data on this subject are ambiguous 
and contradictory [5 - 10]. 
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OBJECTIVE: 
To study distribution allelic variants of MGP T
-138→C (rs1800802) and G-7→A 
(rs1800801) promoter, Thr83→Ala exon 4 (rs4236) polymorphisms in patients with 
acute coronary syndrome in the Ukrainian population. 
 
RESEARCH OBJECTIVES: 
 
1 To study distribution of allelic variants of MGP (SNP) polymorphisms in 
healthy patients - representatives of the Ukrainian population 
2. To research the frequency of allelic polymorphisms of MGP in patients with 
acute coronary syndrome. 
3. Perform a statistic analysis of the connectionof different variants of genotype 
with the development of the acute coronary syndrome. 
 
METHODS: 
1. DNA extraction. 
2. Polymerase chain reaction and restriction fragment length polymorphism 
(RFLP) 
3. Electrophoresis  of DNA amplified fragment  
4.  Statistical analysis was made with SPSS 17.0.  
 
THE PRACTICAL SIGNIFICANCE OF THE STUDY: 
The obtained results can be used as a basis for identifying people who are 
predisposed to the development of the SCS  with intention of prevention of the 
diseases and prevent development of complications. 
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LITERATURE REVIEW 
MGP Biochemistry 
Human MGP molecule (molecular mass 10 kDa) consists of 84 aminoacids 
residues, 5 of them are γ- carboxyglutamic acids (Gla) (Fig. 1). Five forms of MGP 
were  detached from several  bones of rats which  contained 79 and 83 residues while  
5 and 1 residues are missing  at the C terminus [11,12,13]. 
Thou in contrast to all known K- dependent proteins, MGP doesn`t have 
propeptide form [13].  
Although MGP contains a high percentage of hydrophilic residues, it is 
exceptionally water-insoluble (solubility <10 pg/ml), that is why its transport by 
plasma can be realized only in compound action with soluble proteins. 
 
 
 
 
 
 
 
 
 
 
 The MGPmolecule has been synthesized, cDNA structure predicts an 84-
residue mature protein and a 19-residue transmembrane signal peptide and also 
contains 3 functional areas from N terminus: (1) transmembrane signal peptide, 
(2)putative recognition site for γ- carboxylase, (3) Gla- containing domain [13]. 
MGP formed in the cells undergoes post-translational modification, which 
consists of the carboxylation of five residues of glutamic acid (Glu) to form γ- 
carboxyglutamic acids (Gla). This reaction is catalyzed by the enzyme γ- glutamyl 
carboxylase (GGCX) and is connected with the oxidation of the reduced form of 
vitamin K (hydroquinone) into the 2,3-epoxide of vitamin K (Fig. 2). Thus, oxidation 
Figure 1. Scheme of the peptide chain of the molecule MGP.  
                Dark circles - glutamic acid residues, which have γ-carboxylation. In   
                position 83 there may be threonine or alanine (polymorphism Tht83Ala) 
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of vitamin K can not occur without of Glu-residues MGP  molecule carboxylation. In 
turn enough vitamin K for carboxylation of MGP reaction depends on the feedback of 
its reduction which is implemented by means of vitamin K- epoxide reducing 
complex (VKOR). 
 
 
 
 
 
 
 
 
 
 
 
 
In addition to γ- carboxylation, MGP can undergo different posttranslation 
modifications, among them (1) specific proteolytic decomposition in C terminal 
molecule area [14,15], and (2) three serine residues phosphorylation in N terminal 
area [16]. 
Following the above reactions, MGP accumulates in the structures of the Golgi 
apparatus and then it is secreted in the extracellular space where its function is 
realized. 
 
MGP gene 
MGP gene in humans is represented by one copy of which is contained in the 
short arm of chromosome 12 (12p12.3-13.1) [13]. It is encoded with 84 amino acid 
residues of the mature protein and 19 residues of transmembrane signal peptides. The 
length of the gene has 3900 nucleotides and consists of four exons separated by three 
large intermediate sequences (introns)  which account for more than 80% of the total 
MGP 
(Glu) 
MGP 
(Gla) 
Glu Gla 
 γ- glutamyl carboxylase 
KH2 KO 
VKOR 
Figure 2. γ-carboxylation of MGP and vitamin K cycle 
                KH2 - reduced form of vitamin K (hydroquinone), KO - oxidized form of     
                vitamin K (epoxide); VKOR - Vitamin K epoxide reductase 
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length of the gene [13] (Fig. 3). Each of the three functional regions of the protein has 
(1) transmembrane signal peptide (2) recognition site γ-carboxylase (3) the domain 
containing the residues of Gla – is encoded by separate exons of the MGP gene 
(exons 1,3,4). Exon 2 encodes a part of a protein, that consists of 11 amino acid 
residues (α-helical domain) and lies between the transmembrane and signal peptide 
recognition site γ-carboxylase. The function of MGP site is not known yet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Such a 4-exon organization is typical for the osteocalcin gene (BGP). It differs 
substantially from the 2-exon organization of genes that encodes for the 
corresponding sections in other well-known vitamin K-dependent proteins. 
Analysis of the promoter of the gene MGP showed that along with the typical 
TATA and CAT-boxes, it contains the control sequences (putative regulatory 
sequences) homologous to the previously identified elements responsible for the 
action of hormones and transcription factors (hormone and transcription factor 
responsive elements). In particular, it identifies two areas of the promoter containing 
potential binding sites for retinoic acid receptor and vitamin D [13]. 
 
5′-end 3′-end exon 1 2 3 4 
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Figure 3. The structure of the gene and localization of MGP single nucleotide 
polymorphisms, three of his. 
NRE – negative-responsive element 
promoter 
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MGP gene polymorphism 
Today,  more than 120 types of single nucleotide polymorphism (SNP) in the 
gene for human MGP are described. Among them, three types of polymorphism are 
the most explored, because of their association with various diseases: (1) T-138C (rs 
1800802), (2) G-7A (rs 1800801), and (3) Ala83Thr (rs 4236) (Fig. 3). 
Polymorphism T-138C which is a promoter as part of the gene has a site that 
forms complexes with nuclear proteins and takes their regulatory impact; G-7A is 
localized in the initial segment of the promoter from which starts the process of 
transcription; Thr83Ala - in the fourth exon encodes for  Gla-domain. The last variant 
SNP determine  the replacement of threonine into the alanine  in the penultimate 83 
molecules of MGP. 
The question of how different types of MGP gene polymorphism affect its 
expression and the ability to perceive a variety of regulatory influences is now the 
focus of researchers. As one of the methods of approach to the solution, the 
incorporation of genetic constructs into the cultured cells containing the "normal" and 
"pathological" promoter variants of MGP and luciferase gene (luciferase test)  is 
used. 
The first kind of a research was fulfiled by Herrmann et al. [5]. The authors 
showed that the G-7A polymorphism does not affect the promoter activity of the gene 
MGP, meanwhile promoter activity with a minor allele of-138C (pathological 
variant), when compared with-138T (normal variant), was less than 20% in the MMC 
of rat vessels and 50% in cultured human fibroblasts. 
Quite different results were obtained in the Farzaneh et al research. [6]. The 
authors found that the promoter polymorphism G-7A and T-138C significantly alter 
the transcriptional activity of a MGP gene in MMCof rats vessels in vitro. Thus, the 
promoter variant  with minor allele-7A revealed activity in 1.5-times higher than-7G, 
and-138C variant was 4 times as active as -138T. 
Analysis of the MGP gene promoter showed that the T-138C polymorphism 
regard to the site  which is critical for the processes of transcription in vascular 
MMC. Here, in the position between -142 and -136 is an element that can bind  the 
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activation protein-1 (AP-1). It is ascertained, that the T-138C polymorphism changes 
the binding site of the promoter with AP-1 complex. Alternative promoter allele-
138T links good complexes AP-1, composed of c-Jun, JunB, Fra-1 and Fra-2 and 
activated phorbol compounds, while he ability to bind the AP-1 and subsequent 
activation of a promoter with -138C allele is very low [6]. 
The above data confirmed the work of  Kobayashi et al. [7] which found that 
the promoter variant-138T  in contrast to the-138C  can form complexes with nuclear 
proteins (AP-1). However, what concerns us with the activity of these variants are  
the Japanese researchers who came to quite different than Farzaneh et al. 
conclusions: the introduction of MGP gene promoter in cultured cancer cells of 
human mammary gland  have promoter activity -138T allele that was significantly 
higher than with the allele -138C. 
Thus, the contradictory data about the effect of different types of MGP gene 
polymorphism on its transcription activity  indicate the complexity of the problem 
and require further research in this direction. 
 
MGP and calcification of the vascular wall 
The presence of Gla-containing proteins in the vascular wall was first shown 
by J.B. Lian et al. [37] who extracted the Gla amino acid from alkaline hydrolysates 
of calcified atheromatous plaques of human aorta. There was no Gla in the 
hydrolysates of uninjured vessels and in calcificated atherosclerotic plaques which 
gave grounds for the finding of a close connection between the Gla-containing 
proteins and processes of ectopic calcification. 
R. L. Levy et al. [38] with EDTA-extraction isolated protein fraction containing 
Gla from atherosclerotic arteries. Low level of this fraction of protein was typical for 
the fatty strips and plaque, meanwhile in the calcified plaques its rate was 
considerable. The authors assumed that they had discovered a unique Gla-protein 
called atherocalcinom (molecular mass 80 kDa ,19 Gla-residues for 1000 amino 
acids). Subsequently, later the authors reported that atherocalcin  was an artifact 
caused by contamination of blood vessels with serum proteins [39]. 
 10 
After the discovery of MGP , it has been shown that Gla-containing proteins 
are represented by this protein in the walls of blood vessels [40]. In the arterial wall  
the MGP is synthesized in MMC of  media and intima, in areas of atherosclerotic 
affected areas   and macrophages [41]. Using monoclonal antibodies it was shown 
that in normal artery wall of human MGP is associated with MMC and elastic 
membranes in the media and with the extracellular matrix in the adventitia [42]. It 
was found that MGP is related to different types of arterial calcification. 
MGP and atherosclerosis. Calcification of atheromatous plaques is one of the 
process that completes the development of degenerative changes in the intima [43-
45]. The research of accumulation and the expression of MGP in the human plaques 
showed that the protein molecules have a close spatial connection with the places of 
hydroxyapatite deposits: they were found on the border with the calcification of the 
cells [41,42]. However, MGP gene expression (corresponding to the formation of 
mRNA) in the MMC of atheromatous plaques was lower than with normal MMC 
constitutively expressing  this protein. At the same time in plaques MMC began 
synthesis proteins related to the processes of osteo/chondrogenesis (osteocalcin, bone 
sialoprotein, alkaline phosphatase)  and normaly can not be synthesized in the arterial 
wall. These data gave reason to assume that the mineralization patterns of the 
vascular wall may be the result of an imbalance between procalcitonin (osteo / 
chondrogenesis) and anticalcitonin genic factors. MGP belongs to this group.  [41]. 
MGP and Mënkenberg' s arteriosclerosis. The close spatial connection 
between the MGP and cell calcification was found in the arteries of amputated 
extremities of diabetic patients. The deposition of calcium salts in the tunica media of 
arteries (arteriosclerosis Menkeberga) was accompanied, as in case of  
atherosclerosis, with a decrease of MGP gene expression in MMC vessels [41,42]. 
Against the background of these changes MMC began to express the osteogenic 
proteins (see above). For Menkenberg' s arteriosclerosis the close relationship of 
MGP sites and elastic membranes, in plases of vascular calcification disappears but in 
humans and in rats a significant amount of MGP were found in the extracellular 
matrix at the boundary of media with centre of mineralization [42]. 
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MGP and calcification of MMC of blood vessels in vitro. When vascular MMC 
is cultured, it loses its contractile phenotype and gets the features of the modified 
MMC (migration, proliferation, synthesis of connective tissue components), 
characteristics of MMC atherosclerotic plaques. Later, vascular MMC  form multi-
cellular units in vitro  which are spontaneous calcificated after 30 days. Since the first 
signs of this process MGP gene expression and some of osteogenic protein 
(osteocalcin, bone sialoproteins) increases in MMC [34,46,47]. On the other hand, 
there is a data that in the simulation of vascular MMC calcification, MGP expression 
in these bulls cells is reduced [48]. It returns to its original level if the process of 
mineralization is inhibited with bisphosphonates. 
Thus, based on the fact that the expression of MGP in calcification process 
may decrease as well as rise, it has been suggested two possible versions of events. 
The first is that the factors that inhibit MGP gene expression, may promote vascular 
mineralization. Second - in the case of initiation of calcification mechanisms it may 
increase the expression of adaptive proteins that limit this process. It is considered, 
that MGP is one of such protein. [46]. 
In addition to influence on the development of cardiovascular diseases, MGP 
allelic polymorphism may be related to some other illnesses and pathological 
processes   such as kidney stones [49], osteoporosis [50.51], tooth loss [52] and 
plumbum intoxication [53, 54]. 
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MATERIALS AND METHODS 
Into the study were taken 115 patients (70.0% males and 30.0% females) with 
ACS 40 to 83 years old (mean age 58.5  0.7 years) hospitalized to the reanimation 
and intensive therapy department of National Scientific Center "M.D. Strazhesko 
Institute of Cardiology”, National Medical Academy of Science, Ukraine. Unstable 
angina pectoris (UAP) and acute myocardial infarction (MI) as a final diagnosis were 
established in 41 % and 59 % of patients, respectively. In 23 patients MI with no 
peak Q in electrocardiogram (ECG) was diagnosed while in 45 patients with MI peak 
Q was present in ECG. Diagnosis of acute MI and UAP were established on the basis 
of clinical, electrocardiography and biochemical examinations according to the 
recommendations of WHO experts and also according to recommendations of 
European and American cardiologic societies 55-57. Patients with hereditary and 
innate diseases, severe metabolic pathologies including a severe form of diabetes 
mellitus, marked renal and liver failures, deficiencies of the haemostatic system, 
oncology and systemic pathologies, chronic heart failure of IIB-III stage, true 
cardiogenic shock were not included to the studied group. The control group 
consisted of 110 clinically healthy individuals with the absence of cardio-vascular 
pathologies, as confirmed by anamnesis, ECG examination, and measurement of 
arterial pressure and biochemical data. The control group and a group of patients did 
not differ by age and the ratio of persons of both sexes (P> 0,05 for the χ2-test). 
Blood sampling was performed under sterile conditions into 2.7 ml monovettes 
containing EDTA potassium salt as an anticoagulant (Sarstedt, Germany), samples 
were frozen and stored at -20ºC. DNA for genotyping was extracted from the venous 
blood using Isogene kits (Russia) according to manufacturer’s protocol.  
MGP Т-138→С polymorphism (rs1800802) was determined using PCR with 
subsequent analysis of restriction fragments length. For this aim a certain site of the 
MGP gene promoter was amplified using a pair of specific primers (Table 1).  
PCR was performed for 33 cycles in a 25 l volume containing 50-100 ng of 
DNA, 5 l 5X PCR-buffer, 1.5 mM magnesium sulfate, 200 M of each dNTP, 20 
pM of each primer and 0.5U of Taq DNA polymerase ("Fermentas", Lithuania). PCR 
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was carried out in a termocycler GeneAmp PCR System 2700 ("Applied 
Biosystems", USA). 6 l of the PCR products (142 bp) were subjected to digestion 
with 3U BseNI ("Fermentas", Lithuania) and incubated at 37С for 18 hours. 
Presence of thymine at the -138 position of promoter prevented restriction, and in the 
case of substitution for cytosine BseNI cleaves the amplified fragment of the 
promoter into two fragments – 118 and 24 bp (Fig. 4 A). 
 MGP Promoter G
-7→A Polymorphism (rs1800801). PCR was performed 
using primers (Table 1) for 33 cycles in a 25 l volume containing 50-100 ng of 
DNA, 5 l 5X PCR-buffer, 1.5 mM magnesium sulfate, 200 M of each dNTP, 20 
pM of each primer and 0.5U of Taq DNA polymerase ("Fermentas", Lithuania). 6 l 
of the PCR product (500 bp) were subjected to digestion with 2U NcoI ("Fermentas", 
Lithuania) and incubated at 37С for 18 hours. In the presence of guanine at the -7 
position of promoter, NcoI restriction enzyme produces two fragments of 240 and 
260 bp in length. Substitution of guanine for adenine prevents restriction and the 
amplified fragment of the promoter (500 bp) can not be cleaved (Fig. 4 B). 
MGP Exon 4 Thr83→Ala Polymorphism (rs4236). PCR was performed using 
primers (Table 1) for 33 cycles in a 25 l volume containing 50-100 ng of DNA, 5 l 
5X PCR-buffer, 1.5 mM magnesium sulfate, 200 M of each dNTP, 20 pM of each 
primer and 0.5U of Taq DNA polymerase ("Fermentas", Lithuania). 6 l of the PCR 
product (173 bp) were subjected to digestion with 3U Eco477 ("Fermentas", 
Lithuania) and incubated at 37С for 18 hours. Presence of adenine at the 3748 
position of exon 4 prevented digestion, and in the case of substitution for thymine 
Eco477 cleaves the amplified fragment of exon 4 into two fragments – 127 and 46 bp 
(Fig. 4 C).  
Table 1.  
Details of PCR and RFLP for polymorphism analysis. 
 
Polymorphisms Primers 
Annealing 
temperature 
(time) 
PCR 
product 
size (bp) 
Restriction 
enzymes 
Fragments 
after 
restriction 
T
-138→C 
(rs1800802)  
(F) 5`-AAGCATACGАТGGCCAAAACTTCTGCA-3` 
(R) 5`-GAACTAGCAТТGGAACTTTTCCCAACC-3` 
57С (1 min) 142 bp BseNI 118 and 24 bp 
G
-7→A 
(rs1800801) 
(F) 5`-CTAGTTCAGTGCCAACCCTTCCCCACC-3` 
(R) 5`-TAGCAGCAGTAGGGAGAGAGGCTCCCA-3` 
64,5С (45 s) 500 bp NcoI 240 and 260 bp 
Thr83→Ala 
(rs4236) 
(F) 5`-TCAATAGGGAAGCCTGTGATG-3`.  
(R) 5`-AGGGGGATACAAAATCAGGTG -3` 
64,5С (45 s) 173 bp Eco477 127 and 46 bp 
 The RFLP results were analyzed by electrophoresis on an ethidium bromide-
stained 2.5% agarose gel and detected by UV transillumination ("Biocom", Russia). 
 
 
 
Fig. 4. Results of electrophoresis of restriction fragments of amplification products of MGP 
polymorphisms.  
A – T-138→C: lines 4, 5, 7, 9-11 - T/T genotype,  1-3, 8, 12 – T/С genotype, 6 – С/С genotype;  
B - G
-7→A: lines 2, 3, 11 - G/G genotype, 1, 4, 5, 7, 8, 10 - G/А genotype, 6, 9, 12 - А/А genotype; 
C - Thr83→Ala: lines 1, 3, 6, 11 - Thr/Thr genotype, 4, 5, 7-10, 12 - Thr/Ala genotype, 2 - Ala/Ala 
genotype. 
 
Results and Discussion 
Clinical characteristics of studied groups of 115 patients with ACS and 140 
healthy humans are summarized in table 2. No differences between the groups were 
noted with respect to gender, age and glucose concentration. The prevalence of 
atherogenic risk factors (including cigarette smoking, overweight, hypertension, total 
cholesterol) was significantly higher in the patient group. 
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Table 2.  
Clinical parameters of acute coronary syndrome (ACS) and control subjects 
(mean and ± SE) 
 
Parameter Acute Coronary Syndrome 
(n=115) 
Healthy Subjects 
(n=140) 
Sex, male/female 93/22 78/32 
Age, years 58.7  0.5 54.0  0.8 
Current smokers, % 36.5 25.7 
BMI, kg/m
2
                 28.9 ± 0.41              23.8 ± 1.20 * 
SBP, mm Hg                 145.8 ± 2.6              131.6 ± 8.3 * 
DBP, mm Hg                 88.4 ± 1.5              72.8 ± 9.7 * 
T-Cho, mmol/L 6.3 ± 0.13    5.6 ± 0.25 * 
HDL-Cho, mmol/L 1.3 ± 0.05 1.4 ± 0.10 
Glucose, mmol/L                 5.8 ± 0.6  4.7 ± 0.7 * 
 
BMI – body mass index, SBP – systolic blood pressure, DBP - diastolic blood pressure, T-Cho – 
total cholesterol, HDL-Cho – cholesterol of high density lipoproteins. * - p < .05 
 
 
Association between Manifestations of ACS and Polymorphisms of MGP 
Gene. Results of genotyping of the patients by 3 sites of MGP are summarized in 
table 3. 
Table 3. 
 Comparison of genotype for several polymorphisms of MGP gene in patients with 
acute coronary syndrome (ACS) and control subjects 
Genotype 
Promoter 
T
-138→C 
Promoter 
G
-7→A 
Exon 4 
Thr83→Ala 
Control 
(n=139) 
ACS 
(n=107) 
Control 
(n=140) 
ACS 
(n=114) 
Control 
(n=128) 
ACS 
(n=115) 
AA, n (%) 
Aa, n (%) 
aa, n (%) 
75 (54.0) 
57 (41.0) 
7 (5.0) 
64 (59.8) 
35 (32.7) 
8 (7.5) 
71 (50.7) 
63 (45.0) 
6 (4.3) 
48 (42.1) 
52 (45.6) 
14 (12.3) 
58 (45.3) 
55 (43.0) 
15 (11.7) 
49 (42.6) 
50 (43.5) 
16 (13.9) 
Values are n (%). A – major allele, a – minor allele  
  
 As it can be seen, distribution of major allele homozygotous, heterozygotes 
and minor allele homozygotes while analyzing G
-7
→A polymorphism of the 
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promoter was 42.1%, 45.6%, 12.3% correspondingly (in the control group 50.7%, 
45.0%, 4.3%). Analysis of T
-138
→C promoter polymorphism has shown that the 
respective figures were 59.8%, 32.7%, 7.5% (in control group – 54.0%, 41.0%, 5.0%) 
while at the assay of Thr83→Ala polymorphism (exon 4) these were 42.6%, 43.5%, 
13.9% (in control group – 45.3%, 43.0%, 11.7%). In the group of healthy individuals 
a minor allele variant A/A (G
-7→A polymorphism) was observed in 2.9-folds more 
rare than in ACS. Using logistic regression analysis (table 4) it was estimated that 
A/A genotype (G
-7→A polymorphism) was significantly (p=.02) associated with 
ACS (OR=4.302; 95% CI, 1.262 - 14.673) (Fig. 5) 
 
 
 
 
Fig. 5. Determination of the frequency of different genotypes with MGP gene allelic 
polymorphism in the genes of healthy individuals (light columns) and patients with acute coronary 
syndrome (dark columns): A - T-138 → C polymorphism, B - G-7 → A polymorphism; C  - Thr83 
→ Ala polymorphism 
 
A 
C 
В 
Table 4. 
Results of logistic regression analysis 
 
SNP Genotype 
Coefficient of 
regression  
SE 
Wald 
statistics 
P -
value 
OR 
95% CI for 
OR 
lower 
95% CI for 
OR 
upper 
Promoter  
T
-138→C 
T/C - .185 .287 .416 .519 .831 .474 1.458 
C/C .502 .584 .738 .390 1.651 .526 5.189 
Promoter  
G
-7→A 
G/A .431 .351 1.502 .220 1.538 .773 3.064 
A/A 1.459 .626 5.434 .020 4.302 1.262 14.673 
Exon 4 
Thr83→Ala 
Thr/Ala - .247 .358 .479 .489 .781 .387 1.574 
Ala/Ala - .402 .509 .623 .430 .669 .247 1.814 
 
Homozygotes by major allele were considered as a reference group.  
SE – standard error, OR – odds ratio, CI – confidential interval 
 In the present study we have explored associations between genetic variation in 
MGP gene and ACS risk. Analyzing MGP SNPs we have found that G
-7
→A 
promoter polymorphism is associated with ACS in male but not in female 
individuals. As to other two studied polymorphisms (T
-138
→C, Thr83→Ala), we have 
not found any relations (using logistic regression) between them and ACS in the 
Ukrainian population. 
Herrman et al. have analyzed MGP polymorphism in the ECTIM Study which 
included myocardial infarction patients and control subjects from Northern Ireland 
and France, and the AXA study which consisted of health volunteers from France [5]. 
In the ECTIM Study, the genotype distributions did not differ between patients with 
myocardial infarction and control subjects. Only in a group of low-risk subjects were 
the Ala83 and A
-7
 alleles are more frequent in case than in control subjects. In the 
AXA Study, none of the MGP polymorphisms was related to calcification or 
atherosclerosis of the carotid artery. On the other hand, the A
-7
 and Ala83 alleles were 
associated with femoral calcification in the presence of atherosclerotic plaques. Most 
probably, the difference in findings between the carotid and femoral arteries might be 
explained by the significantly lower frequency of atherosclerotic/calcified plaques in 
the carotid than in the femoral arteries. According to these observations, the G
-7
→A 
or Thr83→Ala polymorphism could influence the calcification process affecting 
atherosclerotic plaques, and it might contribute to the risk of myocardial infarction in 
low-risk individuals. The authors considered that it would be necessary to verify 
these results in other studies before any definitive conclusion can be drawn, 
especially since the associations were observed in subgroups of patients and not in 
the whole population. 
In another study, associations between MGP SNPs and coronary artery 
calcification (CAC) in older men and women of European descent from 
Massachusetts (USA) were examined [58-60]. Various methods of analysis all 
revealed that in men, homozygous carriers of the minor allele of G
-7
→A, T
-138
→C 
and Thr83→Ala polymorphisms were associated with a decreased quantity of CAC, 
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relative to major allele carriers. This association was not found in women. In 
addition, genetic variation in MGP was shown to associate with serum MGP 
concentrations, but there were no association between serum MGP and CAC. 
In the Coronary Artery Risk Development in Young Adults (CARDIA) Study, a 
population-based investigation of cardiovascular disease in younger African-
American and non-Hispanic white participants, T
-138
→C polymorphism of the MGP 
gene was analyzed for association with presence or absence of CAC [9]. This SNP 
was also studied in autopsy samples for an association with several measures of 
atherosclerotic calcification [61]. However, no association with T
-138
→C 
polymorphism and measures of vascular calcification was found in either of these 
studies. 
Italian scientists defined the distribution of two MGP polymorphisms (G
-7
→A, 
T
-138
→C) in patients with chronic kidney disease (CKD) and age- and sex-matched 
healthy controls [18]. It was shown that the frequency of the minor A allele (G
-7
→A 
polymorphism) and the major T allele (T
-138
→C polymorphism) was significantly 
higher in the CKD group versus controls. A/A and T/T homozygotes were associated 
with cardiovascular events in CKD patients. It was concluded that altered MGP gene 
polymorphism may be a negative prognostic factor for the progression to end-stage 
renal disease and for cardiovascular events in patients with CKD. 
Thus, findings presented here are inconsistent. In some studies, MGP 
polymorphisms were shown to associate with arterial calcification and myocardial 
infarction [5, 10, 25], in others, no association between MGP SNPs and 
cardiovascular events was found [7, 9]. Moreover, in those studies, in which such 
association was still revealed, relation the same type of MGP polymorphism to 
arterial calcification was different. For example, in AXA Study the minor alleles -7A 
and 83Ala were associated with increased femoral artery calcification [5], while in 
Crosier et al. study [10] the same alleles were linked to decreased level of coronary 
artery calcification. 
In vitro studies results do not clarify the question. In one investigation [15], 
analysis of MGP promoter activity revealed that the -138C allele reduced promoter 
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activity by 20% in rat vascular smooth muscle cells (VSMC) and by up to 50% in a 
human fibroblast cell line. Moreover, it was demonstrated that a nuclear protein 
specifically binds in the region covering the T
-138
→C polymorphic site and that 
binding is enhanced in the presence of the T allele. Thus, the difference in promoter 
activity might be explained by differential binding of a nuclear protein that is 
important in MGP transcription. As regards the G
-7
→A polymorphism, the findings 
did not indicate that this SNP may be functional in vitro. 
At the same time in another study [6], the influence of G
-7
→A and T
-138
→C 
polymorphisms on gene expression was examined by using reporter gene constructs 
transiently transfected into VSMCs. It was demonstrated independent impact of both 
common polymorphisms on transcriptional activity of the MGP gene. The -7A 
variant had 1.5-fold higher activity than the -7G variant, whereas the -138C variant 
had 4-fold higher activity than the -138T variant. On the other hand, it was shown 
that the -138T allelic variant binds AP-1 complexes and is induced following phorbol 
12-myristate 13-acetate treatment, while the -138C variant is refractive to this 
compound, confirming that AP-1 factors preferentially bind to the -138T variant. It 
was suggested that the -138C variant provides protection against tissue calcification 
in VSMC by resulting in higher levels of MGP transcription. Equally, the 
responsiveness of the -138T site to extracellular stimuli mediated via AP-1 may result 
in altered susceptibility to calcification. It is easy to see that these results are in the 
disparity with above mentioned findings [5]. 
In conclusion, we have defined significant association between the G
-7
→A 
promoter polymorphism of MGP gene and ACS (unstable angina pectoris + acute 
myocardial infarction) in Ukrainian population. The observed association suggest 
possible involvement of this polymorphism in coronary artery disease; however, 
these results must be substantiated in other studies focusing on appropriate end 
points. 
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Conclusion 
1. Distribution of major allele homozygotous, heterozygotes and minor allele 
homozygotes in control group while analyzing T
-138→С promoter polymorphism 
58,7%, 36,7%, 4,6 while analyzing G
-7
→A polymorphism of the promoter was -  
41,8%, 54,5%, 3,6% , while at the assay of Thr83→Ala polymorphism (exon 4) 
these were – 43,9%, 45,9%, 10,2%. 
 
2. Distribution of major allele homozygotous, heterozygotes and minor allele 
homozygotes  in group with acute coronary syndrome: while analyzing T
-138→С 
MGP promoter polymorphism were 59,8%, 32,7%, 7,5%, while analyzing G
-
7→A promoter polymorphism were -  42,1%, 45,6%, 12,3% , while at the assay 
of Thr83→Ala polymorphism (exon 4) these were– 42,6%, 43,5%, 13,9%.  
 
3. It was estimated that A/A genotype (G-7→A polymorphism) was significantly 
(p=.02) associated with acute coronary syndrome in Ukrainian population. 
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